Novel agent combination therapies are coming to the forefront of chronic lymphocytic leukemia (CLL) research. Here, William Wierda, MD, PhD, of the MD Anderson Cancer Center, Houston, TX, discusses a few key combination therapy trials that are happening at the moment at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden. He speaks about the CAPTIVATE trial (NCT02910583), which combines ibrutinib and venetoclax for previously untreated CLL, and has achieved outstanding remission rates and MRD negativity in the frontline setting. He also touches upon CLL14 (NCT02242942), which combines venetoclax and obinituzumab. Finally, Dr Wierda explores his expectations for future clinical trials, suggesting that the next set of studies will focus on optimizing these novel agent combinations and fully understanding the treatment mechanisms at play.
CAPTIVATE and beyond: combination therapies for CLL
